Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Drug Preparation Room
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer · Source last updated 2024-01-02
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
Percentage of HCPs
Interval / dispersion
Not reported
Time frame
Day 1 of Cycle 6 (each cycle is 21 days)
What was measured
Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Staff will have increased availability for other tasks in the pharmacy; b) Administrative procedures around FDC SC will require less time; c) FDC SC formulations will provide more flexibility for staff in managing their workload; d) Due to ready-to-use FDC SC formulations, potential dosing errors will be avoided; e) Due to ready-to-use FDC SC formulations, there will be less drug wastage; f) Without having to reconstitute the drug, less storage space for FDC SC related supplies will be required in the pharmacy; g) Preparation procedures and associated time staff time commitment will be reduced."
Analysis population: The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.
Groups in this outcome
All Healthcare Professionals
This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
A: P+H IV Followed by PH FDC SC
In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
B: PH FDC SC Followed by P+H IV
In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
All Healthcare Professionals
160
A: P+H IV Followed by PH FDC SC
80
B: PH FDC SC Followed by P+H IV
80
Reported measurements
Statement a): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement a): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement a): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
7.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement a): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
28.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
28.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
28.8
Not reported
Not reported
Not reported
Not reported
Statement a): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
50.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
52.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
48.8
Not reported
Not reported
Not reported
Not reported
Statement a): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
2.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement a): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Statement b): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement b): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
3.8
Not reported
Not reported
Not reported
Not reported
Statement b): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
14.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
16.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
12.5
Not reported
Not reported
Not reported
Not reported
Statement b): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
18.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
17.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
18.8
Not reported
Not reported
Not reported
Not reported
Statement b): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
46.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
46.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
46.3
Not reported
Not reported
Not reported
Not reported
Statement b): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
2.5
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
2.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement b): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Statement c): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement c): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement c): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
13.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
15.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
11.3
Not reported
Not reported
Not reported
Not reported
Statement c): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
26.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
28.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
23.8
Not reported
Not reported
Not reported
Not reported
Statement c): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
48.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
50.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
47.5
Not reported
Not reported
Not reported
Not reported
Statement c): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement c): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Statement d): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement d): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement d): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
5.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement d): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
23.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
26.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
20.0
Not reported
Not reported
Not reported
Not reported
Statement d): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
56.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
60.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
52.5
Not reported
Not reported
Not reported
Not reported
Statement d): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement d): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
12.5
Not reported
Not reported
Not reported
Not reported
Statement e): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement e): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement e): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
8.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
11.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
6.3
Not reported
Not reported
Not reported
Not reported
Statement e): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
21.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
21.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
22.5
Not reported
Not reported
Not reported
Not reported
Statement e): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
55.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
58.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
51.3
Not reported
Not reported
Not reported
Not reported
Statement e): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement e): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Statement f): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement f): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
4.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement f): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
11.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
16.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
7.5
Not reported
Not reported
Not reported
Not reported
Statement f): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
24.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
20.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
28.8
Not reported
Not reported
Not reported
Not reported
Statement f): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
48.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
53.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
42.5
Not reported
Not reported
Not reported
Not reported
Statement f): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
1.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
1.3
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement f): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Statement g): Strongly Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.6
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
1.3
Not reported
Not reported
Not reported
Not reported
Statement g): Disagree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
0.0
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
0.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
0.0
Not reported
Not reported
Not reported
Not reported
Statement g): Neutral
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
6.9
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
8.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
5.0
Not reported
Not reported
Not reported
Not reported
Statement g): Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
31.3
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
30.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
32.5
Not reported
Not reported
Not reported
Not reported
Statement g): Strongly Agree
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
48.8
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
52.5
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
45.0
Not reported
Not reported
Not reported
Not reported
Statement g): Not Applicable
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
3.1
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
3.8
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
2.5
Not reported
Not reported
Not reported
Not reported
Statement g): Answer Missing
Values in Percentage of HCPs · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
All Healthcare Professionals
9.4
Not reported
Not reported
Not reported
Not reported
A: P+H IV Followed by PH FDC SC
5.0
Not reported
Not reported
Not reported
Not reported
B: PH FDC SC Followed by P+H IV
13.8
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
1.3
group Id
OG001
value
1.3
group Id
OG002
value
1.3
title
Statement a): Strongly Disagree
categories
measurements
group Id
OG000
value
0.6
group Id
OG001
value
1.3
group Id
OG002
value
0.0
title
Statement a): Disagree
categories
measurements
group Id
OG000
value
7.5
group Id
OG001
value
8.8
group Id
OG002
value
6.3
title
Statement a): Neutral
categories
measurements
group Id
OG000
value
28.8
group Id
OG001
value
28.8
group Id
OG002
value
28.8
title
Statement a): Agree
categories
measurements
group Id
OG000
value
50.6
group Id
OG001
value
52.5
group Id
OG002
value
48.8
title
Statement a): Strongly Agree
categories
measurements
group Id
OG000
value
2.5
group Id
OG001
value
3.8
group Id
OG002
value
1.3
title
Statement a): Not Applicable
categories
measurements
group Id
OG000
value
8.8
group Id
OG001
value
3.8
group Id
OG002
value
13.8
title
Statement a): Answer Missing
categories
measurements
group Id
OG000
value
5.6
group Id
OG001
value
8.8
group Id
OG002
value
2.5
title
Statement b): Strongly Disagree
categories
measurements
group Id
OG000
value
3.8
group Id
OG001
value
3.8
group Id
OG002
value
3.8
title
Statement b): Disagree
categories
measurements
group Id
OG000
value
14.4
group Id
OG001
value
16.3
group Id
OG002
value
12.5
title
Statement b): Neutral
categories
measurements
group Id
OG000
value
18.1
group Id
OG001
value
17.5
group Id
OG002
value
18.8
title
Statement b): Agree
categories
measurements
group Id
OG000
value
46.3
group Id
OG001
value
46.3
group Id
OG002
value
46.3
title
Statement b): Strongly Agree
denoms
counts
group Id
OG000
value
160
group Id
OG001
value
80
group Id
OG002
value
80
units
Participants
description
Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Staff will have increased availability for other tasks in the pharmacy; b) Administrative procedures around FDC SC will require less time; c) FDC SC formulations will provide more flexibility for staff in managing their workload; d) Due to ready-to-use FDC SC formulations, potential dosing errors will be avoided; e) Due to ready-to-use FDC SC formulations, there will be less drug wastage; f) Without having to reconstitute the drug, less storage space for FDC SC related supplies will be required in the pharmacy; g) Preparation procedures and associated time staff time commitment will be reduced."
groups
description
This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG000
title
All Healthcare Professionals
description
In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG001
title
A: P+H IV Followed by PH FDC SC
description
In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
id
OG002
title
B: PH FDC SC Followed by P+H IV
param Type
NUMBER
population Description
The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6.
reporting Status
POSTED
time Frame
Day 1 of Cycle 6 (each cycle is 21 days)
title
Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Drug Preparation Room
Triangle